Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference
April 03 2019 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that
Willie Quinn, Chief Financial Officer and Senior Vice President,
Finance and Corporate Development of Sunesis, will present at the
Needham & Company 18th Annual Healthcare Conference on
Wednesday, April 10, 2019 at 2:10 PM Eastern Time at the Westin
Grand Central Hotel in New York City.
A live webcast of the presentation will be available on the
Sunesis website at http://ir.sunesis.com. A replay will
be archived on the "Calendar of Events" page in the Investors and
Media section of the Sunesis website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of hematologic and
solid cancers. Sunesis has built an experienced drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel kinase
inhibitor pipeline, with an emphasis on its oral non-covalent BTK
inhibitor vecabrutinib. Vecabrutinib is currently being evaluated
in a Phase 1b/2 study in adults with chronic lymphocytic leukemia
and other B-cell malignancies that have progressed after prior
therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in
preclinical development. PDK1 is a master kinase that activates
other kinases important to cell growth and survival including
members of the AKT, PKC, RSK, and SGK families. Sunesis is
exploring strategic alternatives for vosaroxin, a late-stage
investigational product for relapsed or refractory AML. Sunesis
also has an interest in the pan-RAF inhibitor TAK-580 which is
licensed to Takeda. TAK-580 is in a clinical trial for pediatric
low-grade glioma.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
Investor and Media
Inquiries:Maeve ConneightonArgot Partners212-600-1902 |
Willie
QuinnSunesis Pharmaceuticals Inc.650-266-3716 |
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2024 to May 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From May 2023 to May 2024